News
Why Pharma Is Exploring Direct-to-Employer Benefit Models
16+ hour, 47+ min ago (350+ words) Why Pharma Is Exploring Direct-to-Employer Benefit Models'Pharmaceutical Commerce In the final installment of his three-part interview series, Jay Bregman, founder and CEO of Andel, discusses the factors contributing to pharmaceutical manufacturers" growing interest in engaging employers more directly, as well…...
Rising GLP-1 Demand Pressures Conventional Employer Drug Benefits
6+ day, 13+ hour ago (126+ words) Jay Bregman, founder and CEO of Andel, discusses how employers are managing rising costs for prescription benefits and how pharma companies are shifting their distribution patterns. In the second of his three-part Pharmaceutical Commerce interview, Jay Bregman discusses how rising…...
Exploring the Growing Affordability Crisis in Healthcare
2+ week, 3+ day ago (424+ words) In this Q&A, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, discusses rising insurance costs, widening affordability gaps, and growing pressure on the healthcare safety net. Drawing on insights from his experience…...
TrumpRx Launches With MFN-Based Drug Discounts
1+ mon, 2+ week ago (353+ words) The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied. It's now official'TrumpRx has launched. President Trump shared the news last night at a press…...
Your Copay Program Is Protecting Access. Is It Also Protecting Gross-to-Net?
1+ mon, 2+ week ago (850+ words) A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026. Pharma companies allocate enormous amounts of money to copay programs, one of their largest controllable marketing expenses. These programs began as a way…...
Why Direct-to-Patient Is the Pharma Industry’s Next Power Move | Pharmaceutical Commerce
1+ mon, 3+ week ago (366+ words) The status quo in the pharmaceutical supply chain has become untenable. For the past two decades, well-intentioned patient support services have helped a small proportion of new-to-brand patients navigate an irrational system which was never designed for them in the…...
Complexities Behind Choosing and Using Health Insurance
2+ mon, 2+ day ago (260+ words) In the final part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, explains how understanding premiums, coverage trade-offs, and HSAs remains a major challenge for patients'and for…...
Why Employers Are Passing More Healthcare Costs to Workers | Pharmaceutical Commerce
2+ mon, 2+ week ago (388+ words) In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, explains as medical inflation persists and benefit designs strain under rising drug spend'especially GLP-1s'employers are reaching the limits of what they…...
How Public Policy Shifts Are Reshaping Employer Healthcare Costs | Pharmaceutical Commerce
2+ mon, 2+ week ago (300+ words) In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, points out that a Medicaid spending tightens and ACA subsidies lapse, reduced public coverage is driving spillover effects'shifting costs to hospitals, employers,…...
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility
2+ mon, 1+ week ago (344+ words) The company will participate in the Trump administration's direct-to-patient drug platform, while committing $100 billion to US R&D and manufacturing. AbbVie has reached a deal with Trump administration to join TrumpRx, a direct-to-patient platform with a goal to drug prices…...